m6A-centered Disease Response Information
General Information of the Disease (ID: M6ADIS0038)
Name |
Acute kidney failure
|
||||
---|---|---|---|---|---|
ICD |
ICD-11: GB60
|
Full List of Target Gene(s) of This m6A-centered Disease Response
Cellular tumor antigen p53 (TP53/p53)
In total 2 item(s) under this target gene | ||||
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene | [1] | |||
Response Summary | Meclofenamic acid increased Cellular tumor antigen p53 (TP53/p53) mRNA and protein levels in AKI both in vitro and in vivo, and FTO overexpression reduced p53 expression and reversed the MA-induced p53 increase in cisplatin-induced acute kidney injury Acute kidney injury. | |||
Responsed Disease | Acute kidney failure [ICD-11: GB60] | |||
Responsed Drug | Cisplatin | Approved | ||
Target Regulator | Fat mass and obesity-associated protein (FTO) | ERASER | ||
Target Regulation | Down regulation | |||
Pathway Response | Apoptosis | hsa04210 | ||
Cell Process | Cell apoptosis | |||
In-vitro Model | HK2 | Normal | Acipenser baerii | CVCL_YE28 |
In-vivo Model | Induced AKI in c57BL/6 mice by intraperitoneal cisplatin injection and treated the animal with vehicle or an FTO inhibitor meclofenamic acid (MA) for 3 days. | |||
Experiment 2 Reporting the m6A-centered Disease Response by This Target Gene | [1] | |||
Response Summary | Meclofenamic acid increased Cellular tumor antigen p53 (TP53/p53) mRNA and protein levels in AKI both in vitro and in vivo, and FTO overexpression reduced p53 expression and reversed the MA-induced p53 increase in cisplatin-induced Acute kidney injury. | |||
Responsed Disease | Acute kidney failure [ICD-11: GB60] | |||
Responsed Drug | Meclofenamic acid | Approved | ||
Target Regulator | Fat mass and obesity-associated protein (FTO) | ERASER | ||
Target Regulation | Down regulation | |||
Pathway Response | Apoptosis | hsa04210 | ||
Cell Process | Cell apoptosis | |||
In-vitro Model | HK2 | Normal | Acipenser baerii | CVCL_YE28 |
In-vivo Model | Induced AKI in c57BL/6 mice by intraperitoneal cisplatin injection and treated the animal with vehicle or an FTO inhibitor meclofenamic acid (MA) for 3 days. | |||
Fibrinogen alpha chain (FGA)
In total 2 item(s) under this target gene | ||||
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene | [2] | |||
Response Summary | m6A plays an important role in cisplatin induced acute kidney injury and berberine alleviates this process. Cisplatin induced an increase in Slc12a1 protein levels and a decrease in Fibrinogen alpha chain (FGA) and Havcr1 protein levels. However, berberine pretreatment reversed these effects. | |||
Responsed Disease | Acute kidney failure [ICD-11: GB60] | |||
Responsed Drug | Cisplatin | Approved | ||
Cell Process | Metabolic processes | |||
Cell death | ||||
Cell apoptosis | ||||
In-vivo Model | This study investigated the N6-methyladenosine (m6A) methylome of kidneys from three mouse groups: C57 mice (controls), those with CI-AKI (injury group, IG), and those pretreated with berberine (treatment group, TG). | |||
Experiment 2 Reporting the m6A-centered Disease Response by This Target Gene | [2] | |||
Response Summary | m6A plays an important role in cisplatin induced acute kidney injury and berberine alleviates this process. Cisplatin induced an increase in Slc12a1 protein levels and a decrease in Fibrinogen alpha chain (FGA) and Havcr1 protein levels. However, berberine pretreatment reversed these effects. | |||
Responsed Disease | Acute kidney failure [ICD-11: GB60] | |||
Responsed Drug | Berberine | Phase 4 | ||
Cell Process | Metabolic processes | |||
Cell death | ||||
Cell apoptosis | ||||
In-vivo Model | This study investigated the N6-methyladenosine (m6A) methylome of kidneys from three mouse groups: C57 mice (controls), those with CI-AKI (injury group, IG), and those pretreated with berberine (treatment group, TG). | |||
Hepatitis A virus cellular receptor 1 (HAVCR1)
In total 2 item(s) under this target gene | ||||
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene | [2] | |||
Response Summary | m6A plays an important role in cisplatin induced acute kidney injury and berberine alleviates this process. Cisplatin induced an increase in Slc12a1 protein levels and a decrease in FGA and Hepatitis A virus cellular receptor 1 (HAVCR1) protein levels. However, berberine pretreatment reversed these effects. | |||
Responsed Disease | Acute kidney failure [ICD-11: GB60] | |||
Responsed Drug | Cisplatin | Approved | ||
Cell Process | Metabolic processes | |||
Cell death | ||||
Cell apoptosis | ||||
In-vivo Model | This study investigated the N6-methyladenosine (m6A) methylome of kidneys from three mouse groups: C57 mice (controls), those with CI-AKI (injury group, IG), and those pretreated with berberine (treatment group, TG). | |||
Experiment 2 Reporting the m6A-centered Disease Response by This Target Gene | [2] | |||
Response Summary | m6A plays an important role in cisplatin induced acute kidney injury and berberine alleviates this process. Cisplatin induced an increase in Slc12a1 protein levels and a decrease in FGA and Hepatitis A virus cellular receptor 1 (HAVCR1) protein levels. However, berberine pretreatment reversed these effects. | |||
Responsed Disease | Acute kidney failure [ICD-11: GB60] | |||
Responsed Drug | Berberine | Phase 4 | ||
Cell Process | Metabolic processes | |||
Cell death | ||||
Cell apoptosis | ||||
In-vivo Model | This study investigated the N6-methyladenosine (m6A) methylome of kidneys from three mouse groups: C57 mice (controls), those with CI-AKI (injury group, IG), and those pretreated with berberine (treatment group, TG). | |||
Solute carrier family 12 member 1 (SLC12A1)
In total 2 item(s) under this target gene | ||||
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene | [2] | |||
Response Summary | m6A plays an important role in cisplatin induced acute kidney injury and berberine alleviates this process. Cisplatin induced an increase in Solute carrier family 12 member 1 (SLC12A1) protein levels and a decrease in FGA and Havcr1 protein levels. However, berberine pretreatment reversed these effects. | |||
Responsed Disease | Acute kidney failure [ICD-11: GB60] | |||
Responsed Drug | Cisplatin | Approved | ||
Cell Process | Metabolic processes | |||
Cell death | ||||
Cell apoptosis | ||||
In-vivo Model | This study investigated the N6-methyladenosine (m6A) methylome of kidneys from three mouse groups: C57 mice (controls), those with CI-AKI (injury group, IG), and those pretreated with berberine (treatment group, TG). | |||
Experiment 2 Reporting the m6A-centered Disease Response by This Target Gene | [2] | |||
Response Summary | m6A plays an important role in cisplatin induced acute kidney injury and berberine alleviates this process. Cisplatin induced an increase in Solute carrier family 12 member 1 (SLC12A1) protein levels and a decrease in FGA and Havcr1 protein levels. However, berberine pretreatment reversed these effects. | |||
Responsed Disease | Acute kidney failure [ICD-11: GB60] | |||
Responsed Drug | Berberine | Phase 4 | ||
Cell Process | Metabolic processes | |||
Cell death | ||||
Cell apoptosis | ||||
In-vivo Model | This study investigated the N6-methyladenosine (m6A) methylome of kidneys from three mouse groups: C57 mice (controls), those with CI-AKI (injury group, IG), and those pretreated with berberine (treatment group, TG). | |||
References